Previous studies have found an association between uterine leiomyomata (UL) and uterine malignancies. This relation has not been studied in black women, who are disproportionately affected by UL.
We investigated prospectively the association between self-reported physician-diagnosed UL and endometrial cancer in the Black Women’s Health Study. During 1995–2013, 47,267 participants with intact uteri completed biennial health questionnaires. Reports of endometrial cancer were confirmed by pathology data from medical records and cancer registries. Cox regression was used to derive incidence rate ratios (IRR) and 95 % confidence intervals (CI).
There were 300 incident endometrial cancer cases during 689,546 person-years of follow-up. In multivariable models, UL history was associated with a 42 % greater incidence of endometrial cancer compared with no such history (95 % CI 1.12–1.80). IRRs for cancer diagnosed 0–2, 3–9, and ≥10 years after UL diagnosis were 3.20 (95 % CI 2.06–4.98), 0.95 (95 % CI 0.60–1.52), and 1.35 (95 % CI 1.03–1.77), respectively. Stronger overall associations between UL history and endometrial cancer were observed for later stages at cancer diagnosis (IRR = 2.25, 95 % CI 1.09–4.63) and type II/III cancers (IRR = 3.13, 95 % CI 1.64–5.99).
In this large cohort of black women, a history of UL was positively associated with endometrial cancer, particularly type II/III tumors. The strongest association was observed for cancer diagnosed within 2 years of UL diagnosis, a finding that might be explained by greater surveillance of women with UL or misdiagnosis of cancer as UL. However, an association was also observed for cancer reported ≥10 years after UL diagnosis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Black Women’s Health Study
Incidence rate ratio
Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R (2015) The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev 24:1407–1415
Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK (2013) Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 22:233–241
Sherman ME, Carreon JD, Lacey JV Jr, Devesa SS (2005) Impact of hysterectomy on endometrial carcinoma rates in the United States. J Natl Cancer Inst 97:1700–1702
Siegel RL, Devesa SS, Cokkinides V, Ma J, Jemal A (2013) State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. Cancer Epidemiol Biomarkers Prev 22:25–31
Stang A, Hawk H, Knowlton R, Gershman ST, Kuss O (2014) Hysterectomy-corrected incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010. Ann Epidemiol 24:849–854
Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–107
Merrill RM (2008) Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 14:CR24–CR31
Whiteman MK, Kuklina E, Jamieson DJ, Hillis SD, Marchbanks PA (2010) Inpatient hospitalization for gynecologic disorders in the United States. Am J Obstet Gynecol 202(541):e1–e6
Marshall LM, Spiegelman D, Barbieri RL et al (1997) Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90:967–973
Anastasiadis PG, Koutlaki NG, Skaphida PG, Galazios GC, Tsikouras PN, Liberis VA (2000) Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 21:180–183
Pasquali R, Casimirri F, Venturoli S et al (1994) Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 43:706–713
Savelli L, De Iaco P, Santini D et al (2003) Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol 188:927–931
Silva EG, Jenkins R (1990) Serous carcinoma in endometrial polyps. Mod Pathol 3:120–128
Takamizawa S, Minakami H, Usui R et al (1999) Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest 48:193–196
Parker WH, Fu YS, Berek JS (1994) Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83:414–418
Escobedo LG, Lee NC, Peterson HB, Wingo PA (1991) Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol 77:124–128
Fortuny J, Sima C, Bayuga S et al (2009) Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 18:1448–1456
Brinton LA, Sakoda LC, Sherman ME et al (2005) Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 14:2929–2935
Becker ER, Spalding J, DuChane J, Horowitz IR (2005) Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998–2002. J Natl Med Assoc 97:1336–1342
Viswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, Lux LJ, Lohr KN (2007) Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 154:1–122
Rein MS, Nowak RA (1992) Biology of uterine myomas and myometrium in vitro. Seminar Reprod Endocrinol 10:310–319
Rein MS (2000) Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108:791–793
Rein MS, Barbieri RL, Friedman AJ (1995) Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 172:14–18
Andersen J (1996) Growth factors and cytokines in uterine leiomyomas. Seminar Reprod Endocrinol 14:269–282
Andersen J (1998) Factors in fibroid growth. Baillieres Clin Obstet Gynaecol 12:225–243
Buttram VC, Reiter RC (1981) Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 36:433–445
Huet-Hudson YM, Chakraborty C, Suzaki Y, Andrews GK, Dey SK (1990) Estrogen regulates synthesis of epidermal growth factor in mouse uterine epithelial cells. Mol Endocrinol 4:510–523
Tommola P, Pekonen F, Rutanen EM (1989) Binding of epidermal growth factor and insulin-like growth factor I in human myometrium and leiomyomata. Obstet Gynecol 74:658–662
Nelson KG, Takahashi T, Lee DC et al (1992) Transforming growth factor-alpha is a potential mediator of estrogen action in the mouse uterus. Endocrinology 131:1657–1664
Mora S, Diehl T, Stewart EA (1995) Prolactin is an autocrine growth regulator for human myometrial and leiomyoma cells. J Soc Gynecol Invest 2:396
Strauss J, Coutifaris C (1999) The endometrium and myometrium: regulation and dysfunction. In: Yen S, Jaffe JM, Barbieri RL (eds) Reproductive endocrinology. Saunders Press, Philadelphia, pp 218–256
Friedman AJ, Lobel SM, Rein MS, Barbieri RL (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 163:1114–1119
Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531–1543
Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57:205–212
Rosenberg L, Adams-Campbell L, Palmer JR (1995) The Black Women’s Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 50:56–58
Wise LA, Palmer JR, Stewart EA, Rosenberg L (2005) Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women’s Health Study. Obstet Gynecol 105:563–568
Block G, Hartman AM, Naughton D (1990) A reduced dietary questionnaire: development and validation. Epidemiology 1:58–64
Boggs DA, Palmer JR, Wise LA et al (2010) Fruit and vegetable intake in relation to risk of breast cancer in the Black Women’s Health Study. Am J Epidemiol 172:1268–1279
Wise LA, Palmer JR, Spiegelman D et al (2005) Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology 16:346–354
Cox DR (1972) Regression models and life-tables. J Roy Stat Soc 34:187–220
Andersen PK, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann Stat 10:1100–1120
Shwayder J, Sakhel K (2014) Imaging for uterine myomas and adenomyosis. J Minim Invasive Gynecol 21:362–376
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509
Cote ML, Alhajj T, Ruterbusch JJ et al (2015) Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Causes Control 26:287–296
Olson SH, Atoria CL, Cote ML et al (2012) The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev 21:753–760
Setiawan VW, Yang HP, Pike MC et al (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607–2618
Mehine M, Kaasinen E, Makinen N et al (2013) Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 369:43–53
Romero-Perez L, Castilla MA, Lopez-Garcia MA et al (2013) Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Hum Pathol 44:244–254
Bertsch E, Qiang W, Zhang Q et al (2014) MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol 27:1144–1153
Ligon AH, Morton CC (2000) Genetics of uterine leiomyomata. Genes Chromosomes Cancer 28:235–245
Fedele M, Fusco A (2010) HMGA and cancer. Biochim Biophys Acta 1799:48–54
McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB (2012) HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology 60:547–553
Howlader N, Noone AM, Krapcho M et al (2014) SEER cancer statistics review, 1975–2012, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2012/
The authors gratefully acknowledge the contributions of BWHS participants & staff. This research was supported by grants R03-CA169888 (PI: Wise), R01-CA058420 (PI: Rosenberg), and UMI-CA164974 (PI: Rosenberg) from the National Cancer Institute, National Institutes of Health. Data on endometrial cancer pathology were obtained from several state cancer registries (AZ, CA, CO, CT, DE, DC, FL, GA, IL, IN, KY, LA, MD, MA, MI, NJ, NY, NC, OK, PA, SC, TN, TX, VA) and results reported do not necessarily represent their views.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Wise, L.A., Sponholtz, T.R., Rosenberg, L. et al. History of uterine leiomyoma and risk of endometrial cancer in black women. Cancer Causes Control 27, 545–552 (2016). https://doi.org/10.1007/s10552-016-0728-3
- Uterine leiomyoma
- Endometrial cancer
- Prospective studies